A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

Laura RivaShuofeng YuanXin YinLaura Martin-SanchoNaoko MatsunagaSebastian Burgstaller-MuehlbacherLars PachePaul P. De JesusMitchell V. HullMax ChangJasper Fuk-Woo ChanJianli CaoVincent Kwok-Man PoonKristina HerbertTu-Trinh NguyenYuan PuCourtney NguyenAndrey RubanovLuis Martinez-SobridoWen-Chun LiuLisa MiorinKris M. WhiteJeffrey R. JohnsonChristopher BennerRen SunPeter G. Schultz, Andrew SuAdolfo Garcia-SastreArnab K. ChatterjeeKwok-Yung YuenSumit K. Chanda


  • Sumit Chanda’s lab in the Immunity and Pathogenesis Program at Sanford Burnham Prebys Medical Discovery Institute committed to finding a drug to fight coronavirus
  • The project is the largest screening of drugs against the virus to have publicly produced results to date and is expected to begin clinical trials soon
  • The development of a vaccine could require at least 12-18 months, so the team is aims to identify therapeutics that can be repurposed as SARS-CoV-2 antivirals
  • Cultured coronavirus provided by University of Hong Kong’s Yuen Kwok-yung in collaboration with the project
  • Tests conducted by 31 research in institutions across the world found that 30 out of 12,000 drugs seemed to stop the virus from destroying human cells
  • Of the 30 successful drugs, six were characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients

Read full text

Related news coverage:

Can ‘Team Science’ Yield a Covid-19 Treatment?


Show More

Related Articles

Back to top button